ISRCTN19674644已完成未知
Randomised double-blind controlled trial of connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment resistant moderate to severe depression evaluation of efficacy, cost effectiveness and mechanism of action
ottinghamshire Healthcare NHS Foundation Trust0 个研究点目标入组 255 人开始时间: 2018年10月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 255
研究概览
简要总结
2020 Protocol article in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342821/ protocol (added 18/09/2020) 2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35049517/ Magnetic Resonance Imaging Protocol and SARS-CoV-2-Induced Changes (added 21/01/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38228914/ (added 22/01/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 13/10/2021:
- •1. Adults >18 years
- •2. Diagnosis of MDD (defined according to DSM-5) that is treatment resistant (defined as scoring 2 or more (42) on the Massachusetts General Hospital Treatment Resistant Depression staging score (51) See appendix on more detailed scoring of treatment resistance
- •3. HDRS-17 score of 16 or more (moderate to severe depression) (52)
- •4. Capacity to provide informed consent before any trial-related activities
- •Previous inclusion criteria:
- •1. Adults >18 years
- •2. Diagnosis of MDD (defined according to DSM-5) that is treatment resistant (defined as scoring 2 or more on the Massachusetts General Hospital Treatment Resistant Depression staging score)
- •3. Capacity to provide informed consent before any trial-related activities
排除标准
- •Current exclusion criteria as of 02/07/2019:
- •History of bipolar disorder (due to risk of mania) or depression secondary to other mental disorder
- •2. Neurological conditions e.g. brain neoplasm, cerebrovascular events, epilepsy, neurodegenerative disorders, and prior brain surgery
- •3. Standard contraindications to MRI i.e. irremovable metal objects in and around body e.g. cardiac pacemaker, implanted medication pump and pregnancy (any doubt resolved by pregnancy test, women of childbearing age taking precautions against pregnancy) This will include other potential complicated factors such as red tattoo’s which consist of iron on the head, neck and back and claustrophobia (we offer mock scanner testing and training in some sites)
- •4. Major unstable medical illness requiring further investigation or treatment.
- •5. Change in prescribed medication 2 weeks before baseline assessment.
- •6. Prescription of lamotrigine, gabapentin, pregabalin in the 2 weeks prior to baseline assessment.
- •7. Daily prescription of benzodiazepine above 5 mg diazepam equivalents, zopiclone above 7.5 mg, zolpidem above 10 mg or zaleplon above 10 mg. These
- •drugs should not be used intermittently in the 2 weeks before baseline assessment.
- •8. Current substance abuse or dependence defined by DSM-5 criteria)
- •9. Prior TMS treatment.
- •10. At risk of suicidality.
- •11. Potential complicated factors relating to the TMS treatment i.e. hairstyles which would impair magnetic transmission and piercings. (Participants would only be excluded if they chose to not make the changes required to ensure effective treatment.)
- •12. Involved with any other clinical trial at the time of consent or 6 months prior.
- •13. Unable to read or understand English.
- •Previous exclusion criteria:
- •1. History of bipolar disorder (due to risk of mania) or depression secondary to other mental disorder
- •2. Neurological conditions e.g. brain neoplasm, cerebrovascular events, epilepsy, neurodegenerative disorders, and prior brain surgery
- •3. Standard contradictions to MRI i.e. irremovable metal objects in and around body e.g. cardiac pacemaker, implanted medication pump and pregnancy (any doubt resolved by pregnancy test, women of childbearing age taking precautions against pregnancy). This will include other potential complicated factors such as red tattoos which consist of iron on the head, neck and back and claustrophobia (we offer mock scanner testing and training in some sites)
- •4. Major unstable medical illness requiring further investigation or treatment
- •5. Change in prescribed medication in the 2 weeks preceding the start of TMS trial or prescription of lamotrigine, pregabalin, gabapentin or benzodiazepines that act on brain glutamate or GABA (only occasional use of other hypnotic drugs zopiclone, zolpidem, zoleplon and promethazine will be allowed)
- •6. Current substance abuse or dependence (defined by DSM-5 criteria)
- •7. Prior TMS treatment
- •8. At risk of suicidality
- •9. Potential complicated factors relating to the TMS treatment i.e hairstyles which would impair magnetic transmission and piercings (participants would only be excluded if they chose to not make the changes required to ensure effective treatment)
- •10. Involved with any other clinical trial at the time of consent or 6 months prior
- •11. Unable to read or understand English
研究者
相似试验
已完成
不适用
Rituximab versus cyclophosphamide in connective tissue disease-ILDInterstitial lung disease in people with severe connective tissue disease, including systemic sclerosis, idiopathic interstitial myopathy (including polymyositis/dermatomyositis) and mixed connective tissue diseaseRespiratoryISRCTN16474148Royal Brompton & Harefield NHS trust104
已完成
2 期
Vitamin D supplementation compared to placebo in people presenting with their first episode of psychosis neuroprotection desigPsychosisMental and Behavioural DisordersISRCTN12424842King's College London149
已完成
不适用
Probiotics to reduce infections in care home residentsSpecialty: Infectious diseases and microbiologyInfections and InfestationsISRCTN16392920Cardiff University310
已完成
不适用
Enterosgel® in the treatment of Irritable Bowel Syndrome with DiarrhoeaIrritable Bowel Syndrome with diarrhoea (IBS-D)Digestive SystemIrritable bowel syndrome with diarrhoeaISRCTN17149988Enteromed Ltd439
已完成
不适用
Zoledronic acid in the management of malignant pleural mesotheliomaSpecialty: Respiratory disorders, Primary sub-specialty: Respiratory disordersUKCRC code/ Disease: Cancer/ Malignant neoplasms of respiratory and intrathoracic organsMalignant neoplasms of respiratory and intrathoracic organsCancerISRCTN45536692orth Bristol NHS Trust22